the development of a safe and effective vaccine against sars-cov-2 for non-immune individuals is an urgent and critical task for controlling the ongoing epidemic.
Dernière mise à jour : 2020-08-25
Fréquence d'utilisation : 1
Qualité :
Soyez la première personne à voter
Anglais
the fda in the united states approved the first point-of-care test on 21 march 2020 for use at the end of that month.diagnostic guidelines released by zhongnan hospital of wuhan university suggested methods for detecting infections based upon clinical features and epidemiological risk.
Dernière mise à jour : 2020-08-25
Fréquence d'utilisation : 1
Qualité :
Soyez la première personne à voter
Anglais
" a first lab survey revealed that as of calendar week 12/2020 a total of at least 483,295 samples were tested up to and including week 12/2020 and 33,491 samples (6.9%) tested positive for sars-cov-2.in israel, researchers at technion and rambam hospital developed and tested a method for testing samples from 64 patients simultaneously, by pooling the samples and only testing further if the combined sample is found to be positive.in wuhan a makeshift 2000-sq-meter emergency detection laboratory named ""huo-yan"" (chinese: 火眼, or ""fire eye"" in english) was opened on 5 february 2020 by bgi, which can process over 10,000 samples a day. "
Nous utilisons des cookies pour améliorer votre expérience utilisateur sur notre site. En poursuivant votre navigation, vous déclarez accepter leur utilisation. En savoir plus.OK